"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
In controlled clinical trials, the most frequent adverse reactions reported for TEMOVATE (clobetasol propionate cream and ointment) Cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and Assuring of the skin.
In controlled clinical trials, the most frequent adverse events reported for TEMOVATE (clobetasol propionate cream and ointment) Ointment were burning sensation,.irritation, and itching in 0.5% of treated patients. Less frequent adverse reactions were stinging, cracking, erythema, folliculitis, numbness of fingers, skin atrophy, and telangiectasia.
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.
Read the Temovate (clobetasol propionate cream and ointment) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 3/18/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Temovate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.